North 51 acquired by Bionical
pharmafile | October 5, 2015 | News story | | Bionical, North 51, mergers and acquisitions
North 51 Ltd, a Nottingham-based healthcare company has been acquired by Bionical in a multi-million pound deal.
The North 51 founders- Phil Randall, Paul Dermody and Oliver Jackson- will be staying with the business and believe that this exciting development presents North 51 with new opportunities for growth, both in the UK and internationally; especially as Bionical do not currently provide any of the services that North 51 offers and are keen to invest in the future of the business.
Founded in 2004, North 51 has since grown organically to employ almost 150 people. Via three divisions, North 51 delivers recruitment and contract sales solutions to the pharmaceutical industry, creates digital experiences and software products for organisations across the healthcare sector and runs outsourced public health services for the NHS and local authorities.
Bionical is a fast-growing international business based locally in Derbyshire, also specialising in the healthcare sector. The company’s core business is in Clinical Trial Services and the acquisition of North 51 is its second such acquisition in the last few months, having acquired the US-based company, McCallan, in July. McCallan are based just south of New York and specialise in pharma engagement, particularly with primary healthcare professionals.
Graham McIntosh, CEO at Bionical, says: “The acquisition of North 51 enhances Bionical’s commitment to helping Healthcare companies truly engage with their customers be that patients, physicians or payers.”
Phil Randall, CEO at North 51, comments: “The North 51 Directors are delighted with this development. Our discussions with Bionical left us in no doubt that this acquisition would open up a new and exciting phase for North 51 and create many exciting opportunities for our staff.”
Paul Dermody, MD at North 51, adds: “North 51 is very proud to join forces with Bionical. Working together will enable us to develop new and innovative solutions that can only improve the services we offer and provide to our clients.”
Related Content
Transactions in the pharma sector: Through the EU merger review looking-glass
With mergers and acquisitions back in full swing after a period of drought, Alec Burnside …
Bionical adds Emas Pharma in strategic acquisition
Bionical, an integrated outsourced specialist to the pharmaceutical, biotechnology and public health industry, has announced …
Amgen open to larger M&A deals, says CFO
Amgen’s chief financial officer has indicated that the company is ready to consider doing larger …
